Texas at­tor­ney gen­er­al sues Pfiz­er, Tris Phar­ma over man­u­fac­tur­ing is­sues sur­round­ing AD­HD med

Pfiz­er and Tris Phar­ma are at the cen­ter of a new law­suit al­leg­ing they hid man­u­fac­tur­ing prob­lems re­lat­ed to an AD­HD med­ica­tion and de­fraud­ed the Texas Med­ic­aid pro­gram.

Both com­pa­nies have de­nied the ac­cu­sa­tions, and Pfiz­er in­tends to seek a dis­missal “in due course,” the phar­ma gi­ant told End­points News in an email.

The case cen­ters around Quil­li­vant XR, which was ap­proved in Sep­tem­ber 2012 for the treat­ment of AD­HD in pa­tients 6 years and old­er. In a law­suit un­sealed this week, Texas At­tor­ney Gen­er­al Ken Pax­ton al­leges that it wasn’t long be­fore some sam­ples of the drug be­gan fail­ing dis­so­lu­tion tests, which de­ter­mine whether the drug will dis­solve as ex­pect­ed once tak­en by a pa­tient. Tris Phar­ma served as Pfiz­er’s con­tract man­u­fac­tur­er for Quil­li­vant at that time be­fore buy­ing the prod­uct line in 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER